For research use only. Not for therapeutic Use.
Uplarafenib (B-Raf IN 10) (Compound C09) is a BRAF inhibitor with an IC50 between 50 and 100 nM. Uplarafenib shows antitumor activity[1].
Uplarafenib (Compound C09) (1 μM) shows more than 89% inhibition against BRAF and BRAF V600E[1].
Uplarafenib shows an IC50 between 50 and 100 nM against BRAF, less than 50 nM against BRAF V600E[1].
Uplarafenib (72 h) inhibits A375 and SK-MEL-28 cells growth but not CHL-1 and SK-MEL-31 cells[1].
| Catalog Number | I042905 |
| CAS Number | 1425485-87-5 |
| Synonyms | N-[2,4,5-trifluoro-3-(3-morpholin-4-ylquinoxaline-6-carbonyl)phenyl]propane-1-sulfonamide |
| Molecular Formula | C22H21F3N4O4S |
| Purity | ≥95% |
| InChI | InChI=1S/C22H21F3N4O4S/c1-2-9-34(31,32)28-17-11-14(23)20(24)19(21(17)25)22(30)13-3-4-15-16(10-13)27-18(12-26-15)29-5-7-33-8-6-29/h3-4,10-12,28H,2,5-9H2,1H3 |
| InChIKey | HAYBWDINAFTFCJ-UHFFFAOYSA-N |
| SMILES | CCCS(=O)(=O)NC1=CC(=C(C(=C1F)C(=O)C2=CC3=NC(=CN=C3C=C2)N4CCOCC4)F)F |
| Reference | [1]. Yong-Liang Zhu, et al. Certain Chemical Entities, Compositions, and Methods. Patent US20130053384 A1. |
